COMP <GO>
HIMS vs MRK // ALTMAN Z-SCORE & DEBT/EQUITY
Hims & Hers Health Inc. (NYSE) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: HIMS 3
— MRK 12
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: MRK
LAST: $27.68 (-6.71%) • MKT CAP: $6.92B
balance-sheet
3.95
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
balance-sheet
5.19
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HIMS VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HIMS | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 73.80% | 74.80% | -1.00 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.40% | 20.70% | -12.30 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 37.7x | 15.3x | +22.40 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 2.81% | 3.42% | -0.61 | MRK | /fcf-yield <GO> |
| Operating Margin | 4.50% | 34.30% | -29.80 | MRK | /operating-margins <GO> |
| Net Profit Margin | 5.50% | 28.10% | -22.60 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 59.00% | 1.30% | +57.70 | HIMS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 3.95 | 5.19 | -1.24 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | HIMS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 6.60% | +0.50 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.9 | 56.9 | -11.95 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.05 | 0.92 | +0.13 | HIMS | /macro-sensitivity <GO> |
| Forward P/E Multiple | 45.3x | 18.4x | +26.90 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $6.92B | $361.02B | -$354.10B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HIMS REV | MRK REV | HIMS GROSS % | MRK GROSS % | HIMS FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.35B | $65.01B | 73.8% | 74.8% | $194.4M | $12.36B |
| FY 2024 | $1.48B | $64.17B | 79.5% | 76.3% | $184.6M | $18.10B |
| FY 2023 | $872.0M | $60.12B | 44.0% | 44.0% | $34.2M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HIMS // BETA 1.05
MRK // BETA 0.92